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One of the most important aspects of preparing travelers for destinations throughout the
world is providing them with immunizations. Before administering any vaccines, however, a
careful health and immunization history and travel itinerary should be obtained in order to
determine vaccine indications and contraindications. There are three categories of immuniza-
tions for foreign travel. The first category includes immunizations which are routinely recom-
mended whether or not the individual is traveling. Many travelers are due for primary
vaccination or boosting against tetanus-diphtheria, measles-mumps-rubella, pneumococcal
pneumonia, and influenza, for example, and the pre-travel visit is an ideal time to administer
these. The second category are immunizations which might be required by a country as a
condition for entry; these are yellow fever and cholera. The final category contains immuniza-
tions which are recommended because there is a risk of acquiring a particular disease during
travel. Typhoid fever, meningococcal disease, rabies, and hepatitis are some examples. Travel-
ers who are pregnant or who are infected with the human immunodeficiency virus require
special consideration. Provision ofappropriate immunizations forforeign travel is an important
aspect ofpreventing illness in travelers.
The need to get "travel shots" is probably the most frequent reason for which an
individual visits a physician's office prior to foreign travel. Thisvisit provides an ideal
opportunity to update immunizations routinely recommended for those individuals
residing in the United States, in addition to providing those immunizations which
should be given for a trip. The pre-travel visit is also the time to discuss other
preventive measures, such as those against malaria and traveler's diarrhea, which are
applicable to travel in the developing world [1,2]. Although internists, pediatricians,
and family physicians are able to administer most travel immunizations in their
offices, changing disease patterns and international health requirements, as well as
complex itineraries, make it a difficult task to remain up to date. In addition, the
administration of yellow fever vaccine is restricted by state health authorities, and
other vaccines such as those against rabies or meningococcal meningitis may be too
costly to maintain routinely in an office setting. Many areas now have travel clinics,
runbyspecialists in tropical or travel medicine (emporiatrics), which can provide the
necessary immunizations, advice, and post-travel care at one site. Several excellent
resources discuss immunizations; this review will put their use into the context of
foreign travel [2-7].
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GENERAL CONSIDERATIONS
For each traveler, it is important that a detailed travel itinerary, including the
areas to be visited within each country, duration ofstay, and medical and immuniza-
tion history be obtained before any immunizations are given. A trip to Nairobi,
Kenya, for a week's business conference does not present the same level of health
risk as does prolonged travel for a malaria research project on the shores of Lake
Victoria, even though both trips are to Kenya.
Vaccinations can be divided into thosewhich are routinely recommended whether
or not a person is traveling, such as tetanus-diphtheria, those which are required by
countries as a condition for entry, such as yellow fever, and those which are
recommended because of potential risk during travel, such as typhoid fever. Each
immunization and its schedule for administration is listed in Table 1.
It is important to distinguish between required and recommended vaccines.
Required vaccines are those which one must have prior to being allowed to enter a
country. Recommended vaccines are those which may be needed because infection
could be acquired in the country ofdestination or in a particular location within that
country. As an example, epidemic meningococcal disease only occurs in certain
geographic areas ofthe world, and, ifthe traveler does notvisit these areas, there is
no need for that person to receive vaccine. On the other hand, typhoid fever occurs
throughout the developing world but will be a risk to travelers only if they ingest
untreated liquids or foods in areas of poor sanitation, such as may occur in rural
areas and smallvillages. Forthosediseaseswhich are transmittedbyfecal contamina-
tion ofthe food and water supply, such as travelers' diarrhea, typhoid, poliomyelitis,
cholera, hepatitis A, and giardiasis, the best prevention may be careful selection of
food and liquids. If, however, there is unavoidable exposure to poor sanitation for
more than two to three weeks, then it is reasonable to administer vaccines. For each
of the potentially recommended vaccines, the physician must weigh the risk of
disease acquisition withvaccine efficacy and side effects.
Vaccines are either inactivated viral or bacterial products, such as tetanus toxoid,
typhoid, and rabies, or they are live, but attenuated, bacteria or viruses, such as
yellow fever, oral poliomyelitis, and the new oral typhoid vaccine. Most parenteral
vaccines, whether they are killed or attenuated, can be administered simultaneously
at different sites, although cumulative side effects may preclude this procedure. If
attenuated live viral vaccines cannot be given simultaneously, they should be given
separated by one month. The administration oflive vaccines maybe contraindicated
in certain groups of travelers, such as pregnant women [8] or immunocompromised
hosts, including those with human immunodeficiency virus (HIV) infection [9-12].
These issues will be discussed in the sectionswhich follow, and specific contraindica-
tions are also listed in Table 1. Tables 2 and 3 give general guidelines for the
administration of vaccines to pregnant or HIV-infected travelers, respectively.
Infants and small children can be considered for the same immunizations as adults;
however, the schedule and the administration may need to be altered [2,5,6].
Prior to the administration of any biologic product, the manufacturer's full
prescribing information should be consulted. For each vaccination, the type of
vaccine, date ofadministration, dose, site, manufacturer, and lot number, as well as
any untoward effects, should be recorded in the patient's record [13].
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IMMUNIZATIONS
Routinely RecommendedImmunizations
The pre-travel visit is an ideal time to update routinely recommended immuniza-
tions for both children and adults. The vaccine coverage for many travelers may be
inadequate, putting them at risk for vaccine-preventable disease [14,15]. At the
International Traveler's Medical Service at the University of Connecticut Health
Center, 43 percent of travelers were due for boosting against tetanus-diphtheria, 55
percent of those born in 1957 and later for a primary series or booster for measles,
and 70 percent for poliomyelitis iftheir travel itinerary included a polio risk [14]. In
addition, the wide age range ofthis group (4 percent were 12 years old and younger,
and 13 percent were 65 years and older) provides the opportunity to bring children
up to date onchildhood immunizations and the elderlyon influenza and pneumococ-
cal vaccine. The immunizations listed below can be considered as routinely recom-
mended. Although there has been a recent recommendation to include protection
against hepatitis B as part of routine childhood immunizations, this vaccine will be
discussed in the later section on immunizations recommended because of exposure
[16].
1. Tetanus-Diphtheria Toxoids: Adults over the age of 50 constitute nearly 70
percent oftetanus cases in the United States. Most ofthese occurred in personswho
were never immunized, received an incomplete primary series, or, rarely, had gone
longer than ten years since their last booster [17,18]. In addition, recent antibody
studies also indicate that over 50 percent of adults may be susceptible to diphtheria
[19]. For these reasons, all adults should have completed a primary series of
tetanus-diphtheria and received boosters with the combined toxoids at ten-year
intervals. Children under seven should receive the combined tetanus-diphtheria-
pertussisvaccine.
Some adult travelers maybenefit from a booster oftetanus-diphtheria at a five- to
ten-year interval, because they will not need either tetanus immune globulin or a
booster if they sustain a tetanus-prone wound and have been boosted within five
years [17]. Obtaining immunization before travel may be easier and safer than
receiving an injection in a developing area, where the sterility ofneedles andvaccine
storage conditions maybe inadequate.
2. Measles: In the last few years, recommendations for measles immunization
have been changed to include a two-dose schedule for the primary immunization of
children and revaccination of selected older children and young adults [20,21]. The
reason for this change has been the dramatic increase in measles cases in the United
States in 1989 and 1990, when the number ofannual cases rose nearly tenfold to over
27,000cases [22]. These cases primarilyoccurred in unvaccinated, inner-citychildren
<5 years ofage, and in previouslyvaccinated school and college age individuals (five
to 19 years). Measles which occurs in persons previously vaccinated is thought to be
due to primaryvaccine failure rather than to waning immunity.
Travel overseas may also constitute a substantial measles exposure to the unpro-
tected traveler. From 1983 to 1988, 4 to 22 percent of measles cases (1,478 cases)
were epidemiologically linked within two generations to international travel [23,24],
and about half of the initial cases were in returning Americans. In addition, during
thisperiod, 8 percent ofalloutbreaks ofmeasles in the United States couldbe traced
to an imported case [23,25].
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All international travelers should be immune to measles [26]. Childrentraveling to
high-risk areas where they are likely to be exposed at a young age can be vaccinated
from six to 12 monthswith single-antigen (monovalent) measlesvaccine, and from 12
to 15 months with the trivalent, measles-mumps-rubella vaccine. These children
should be reimmunized at 15 monthswith the trivalentvaccine and should receive an
additional dose at entry to school [20].
Travelers born in 1957 and laterwho have not had physician-documentedmeasles,
laboratory evidence of immunity, or two doses of live vaccine, with the second dose
administered after 1980, should be given a one-time dose ofmeasles vaccine. Ifthey
have never been immunized, they should receive two doses ofvaccine, separated by
at least one month. Those born before 1957 can be considered immune secondary to
natural infection.
3. Rubella, Mumps: Women travelers who are of childbearing age should be
immune to rubella. If they are susceptible, they should be vaccinated to prevent
congenital rubella syndrome [27]. Most adults have been naturally infected with
mumpsvirus; however, if an adult is susceptible, vaccination may be considered [28].
Many physicians will give the trivalent, measles-mumps-rubella vaccine if immunity
to one or more of the three viruses is lacking. The side effects are not increased if a
traveler receives a vaccine to which he or she is already immune. Immune globulin
should not be given less than three months before or two weeks after measles,
mumps, or rubella vaccine so that there is no interference withvaccineimmunogenic-
ity because of the passive transfer of antibodies.
4. Pneumococcal Vaccine: With approximately 13 percent of a travel popula-
tion age 65 years and older, both pneumococcal and influenza immunization become
particularly important. While the efficacy of pneumococcal vaccine in elderly or
chronically ill populations may be limited, it is still recommended for well-defined
risk groups. These risk groups include healthy persons 65 years of age and older and
adults or children .2 years old with chronic illness or immunosuppression, which
predisposes them to a higher risk for complications from bacteremic or pulmonary
infection with the pneumococcus. The vaccine consists of antigenic polysaccharides
from 23 serotypes ofStreptococcuspneumoniae and has replaced the older 14-valent
vaccine [29].
5. Influenza: Influenza occurs throughout the world and is a risk for persons
traveling to the tropics at any time ofthe year or to the Southern Hemisphere during
April to September. Thecomposition ofthe influenzavaccine is determined annually
and includes the viral subtypes of influenza A and B which are projected to cause
disease in the United States [30]. The influenza viruses which are active in the
developing world may or may not, however, be included in the U.S. vaccine [31].
Vaccination is recommended for adults and children who are likely to experience
complications from influenza and for persons such as health care workers, who have
an increased risk of influenza because of exposure [30]. Persons who may have
complications from influenza are those with chronic disorders of the cardiovascular
or pulmonary system, persons with other chronic medical conditions, nursing home
residents, healthypersons age 65 andolder, and children (age sixmonths to 18years)
on chronic aspirin therapy.
6. Haemophilus influenzae Type b: There are now three conjugate vaccines
using the polysaccharide capsule ofHemophilus influenzae type b for the prevention
of invasive H. influenzae disease [32]. Two ofthese, HibTITER<'t and PedvaxHIBS',
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are licensed for use in children beginning at two months of age, and one, ProHIB-
ITV, is licensed for use at age 15 months and older. Each vaccine differs in the
conjugated protein carrier used to stimulate T-cell responses, the size of the
polysaccharide, the method ofchemical conjugation, and the schedule ofadministra-
tion. All children, beginning at age two months, should receive protection againstH.
influenzae as part of their routine childhood immunizations. Those children older
than two months and up to five years of age should receive the vaccine in a modified
dosing schedule [32]. Immunization with the conjugate vaccines does not protect
against the carrier protein, nor does it preclude immunizations with the other
standard vaccines, such as diphtheria and tetanus toxoids and pertussisvaccine.
RequiredImmunizations
Thevaccinations which maybe requiredby a countryprior to allowing the traveler
to enter are yellow fever and cholera. A list of vaccine requirements by country is
published annually by the Centers for Disease Control in Health Information for
International Travel [2]. According to international health regulations, required
vaccinations must be recorded in the document "International Certificate of
Vaccination" [33], and validated by a stamp issued by state health departments. No
vaccinations are required to re-enter the United States by returning U.S. residents.
In 1980, the World Health Organization declared the world free of smallpox.
Accordingly, in 1982, smallpox vaccination was no longer required for international
travel and should not be given for this purpose [34].
1. Yellow Fever: Yellow fever is a viral disease transmitted by mosquitos.
Areaswhere cases ofyellow fever areoccurring are called "infected" areas. These lie
primarily in equatorial South America and in Africa, for approximately 15 degrees
on either side of the equator [35], and can be determined specifically by consulting
the Summary of Health Information for Intemational Travel, published every two
weeks by the Centers for Disease Control [36]. In recent years,jungle yellow fever in
non-human primates has been reported from Trinidad and Tobago [37]. Areas in
Africa and South America where infection could occur, but where cases are not
being reported, are called "endemic zones."
Theyellowfevervaccine shouldbegiven to personswho are traveling toorlivingin
"infected" areas, and to persons who visit rural areas of countries in the "endemic
zones" for yellow fever [38]. Some countries which do not lie in the endemic zones,
particularly those in Asia, may require immunization for persons entering from an
area where yellow fever is occurring. The vaccine is given only in approved vaccina-
tion centers because of its requirement for cold storage and viability for only 60
minutes after reconstitution. One can call state or local health departments to
identify these centers. If cholera and yellow fever vaccines are both given, they
should ideally be separated by a minimum of three weeks, since simultaneous
administration may interfere with the antibody response to each vaccine [39].
Immune globulin does not interfere with the response to yellow fevervaccine.
2. Cholera: The outbreak of cholera which began in January of 1991 in
western South America and has spread to Mexico, Central America, and other areas
ofSouthAmerica, has captured world attention [40]. This outbreak emphasizeswhat
can happen when an infectious agent such as Vibrio cholerae is introduced into a
susceptible population. Although a few cases have occurred in tourists to these areas,
the overall risk of cholera remains extremely low for those who exercise caution in
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food and water sanitation [41,42]. The poor vaccine efficacy, combined with its
uncomfortable side effects, make vaccination infrequently indicated [43]. In accor-
dance with this information, in 1988 the World Health Organization no longer
recommended cholera immunization for international travel. No country requires
administration of cholera vaccine before direct travel from the United States, and
fewer than ten countries require vaccination before entry from a country reporting
cholera, such as entering Pakistan from India orTanzania from Kenya [2].
Personswho maybe considered forvaccination are thosewhowill work and live in
highly endemic areas with poor sanitary conditions and persons with impaired
gastrointestinal defense mechanisms. One dose, properly recorded andgiven at least
six days before travel, is satisfactory for entry into countries requiringvaccination. A
letter of medical contraindication should suffice for those travelers who either
cannot or do not wish to receive vaccine. Studies continue on new oral preparations
ofvaccine [44].
Immunizations RecommendedBecause ofExposure
1. Typhoid: The risk of typhoid fever varies by destination. In a retrospective
reviewoftyphoid cases in the United States, itwas estimated that 0.1 per one million
travelers to Northern Europe compared with over 100 per one million travelers to
India, Pakistan, or Peru will acquire typhoid fever [45]. Two vaccines are currently
available in the United States for protection: the older inactivated vaccine and a
recently released attenuated oral vaccine [46]. A third vaccine, which has not yet
been licensed in the United States, containspurified Vi capsular polysaccharide ofS.
typhi and has approximately 70 percent efficacy over one to two years [47,48].
The attenuated oral vaccine uses the Ty 21a mutant, of S. typhi that produces
enough lipopolysaccharide to be immunogenic but does not undergo sustained
replication [49]. In a large-scale field trial in Chilean school children, it had an
efficacy of 67 percent [50], which is similar to that of the older heat-phenol-
inactivated parenteral vaccine (50 percent to 70 percent). The attenuated vaccine,
however, is easier to give because of its oral route of administration, is better
tolerated by the patient, and can be completed within a week of starting the
procedure. Strict instructions need to be given to recipients to assure vaccine
refrigeration and compliance with each dose given on alternate days for a total of
four doses [51].
Typhoid vaccine should be given to travelers visiting areas endemic for typhoid
fever, where fecally contaminated food and water are likely to be ingested [52].
Travelers to areas where Salmonella typhi is resistant to antimicrobial agents should
also be considered forvaccination. Although it is not stated in the product insert, the
oral typhoidvaccine may interferewith the response to oral poliovaccine, suggesting
that their administration should be separated by at least two weeks [53]. It may also
be best to delay initiation of anti-malarial prophylaxis until a week after completing
oral typhoid vaccine because of the theoretical antimicrobial effect ofanti-malarials
[53].
2. MeningococcalDisease: Several areas of the world have epidemic meningo-
coccal disease, which poses a low, but potential, risk to international travelers [54].
Trekkers in Nepal, travelers to the New Delhi region ofIndia, to Kenya orTanzania,
religious pilgrims to Saudi Arabia, and long-term visitors to sub-Sahara Africa
should be considered at potential risk andvaccinated [54,55]. The epidemic serotype
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is usually type A, which is contained in the current quadrivalent vaccine (groups A,
C, Y, and W-135). Thevaccine is available in single-dose vials.
3. Plague: The efficacy of plague vaccine has not been demonstrated in any
controlled trial. The vaccine is not required by any country, and the risk to an
individual traveler is extremely small; therefore, vaccination is rarely recommended
for international travel [56]. Prophylactic antibiotics may be indicated for the
travelerwith a definite exposure.
4. Tuberculosis prevention: A traveler to the developing world is at risk for
tuberculosis if that person has prolonged contact with respiratory droplets from
infected persons in a closed setting. The approach to these travelers should not be
vaccination with the bacillus of Calmette and Guerin (BCG) vaccine, but pre- and
post-travel tuberculin skin testing [57]. For those rare children who will have
unavoidable exposure to tuberculosis and for whom other preventive measures such
as prophylactic isoniazid have failed or cannot be used, BCG vaccine may be
considered.
5. Poliomyelitis: The decade of the 1990s holds the hope of elimination of
polio from the Americas [58]. Already 30 percent of the world's population lives in
polio-free areas. Poliovirus remains endemicthroughout many areasofthe develop-
ing world, however, particularly in Asia and Africa, and, if vaccine coverage falls,
poliomyelitis can occur in the developedworld aswell [59]. The riskforpoliomyelitis
for an international travelerisextremelysmall [60]. In the UnitedStates,of138cases
ofparalytic polio from 1973 to 1984, only 13 caseswere imported [61]. Nevertheless,
all travelers to areas of risk with exposure to poor food and water sanitation should
be immunized to polio.
There are two vaccines for protection against polio: the oral polio vaccine (OPV;
Sabin, live attenuated trivalent vaccine), and the inactivated polio vaccine of
enhanced potency (eIPV). The eIPVhas replaced the conventional inactivatedpolio
virusvaccine(Salkvaccine). Primaryimmunizationofchildren inthe United Statesis
accomplished with OPV [62]. Because rare cases of paralytic polio are associated
with OPV, it is usually notgiven asprimaryvaccination inadults. Theriskofparalysis
in first-time recipients of OPV and contacts of recipients is approximately one case
per520,000 doses, and, for all subsequent doses, one case per 12.3 million doses [61].
Contacts of vaccine recipients accounted for nearly 60 percent of cases. These
contacts were usually unimmunized or inadequately immunized parents or relatives
of a child who received OPV.
Primaryvaccination for persons 18yearsorolder should be donewith eIPV [63]. If
at least two doses of eIPV cannot be given before protection is required (less than
four weeks before departure), a single dose of either oral polio vaccine or eIPV can
begiven. Ifa person hascompleted or started a primary serieswith either OPVor an
inactivated poliovaccine, either oral polio vaccine or eIPV maybe used to complete
the series or to boost the patient's response. It is recommended that persons who
have completed a primary series receive a one-time booster iftraveling to an area of
risk. Both oral poliovaccine and eIPVprovide long-term immunity and maybe given
with immune globulin.
6. JapaneseBEncephalitis: The risk ofJapanese B encephalitis to the interna-
tional traveler is extremely low; however, rare fatalities have occurred and have
prompted interest in vaccination [64]. Japanese B encephalitis is a mosquito-
transmitted flavivirus infection of the central nervous system, and occurs in temper-
306IMMUNIZATIONS FOR FOREIGN TRAVEL
ate zones (China, Japan [little to no risk], Korea, the lowlands of Nepal, Burma,
Bangladesh, Kampuchea, Laos, northern India, and Thailand, and the eastern part
of the former Union of Soviet Socialist Republics) from June through September,
and in tropical zones (southern India and Thailand, Taiwan, Indonesia, the Philip-
pines, Malaysia, Sri Lanka, and Singapore), throughout the entire year [65]. Over 98
percent of infections are unapparent, but among those patients with symptomatic
disease, the fatality rate is approximately 20 percent, with a high morbidity in
survivors [66,67]. Clinical disease occurs primarily in youngchildren and adultsmore
than 65 years ofage.
Beginning in May 1983, a monovalent inactivated vaccine, purified from mouse
brain (BIKEN, The Research Foundation for Microbial Diseases, Osaka University,
Japan), was studied under an investigational new drug exemption in the United
States. The vaccine was immunogenic and well-tolerated in a three-dose schedule
[68], and in the Far East it has been safe and effective, based on years of use [69].
Nevertheless, because of concern about liability protection, the vaccine was with-
drawn from the United States in July of 1987. Efforts are under way, by the Centers
for Disease Control, Connaught Laboratories, Inc., the Food and Drug Administra-
tion, and the U.S. Army, to obtain a product license.
Persons are at risk for Japanese B encephalitis if they are traveling in endemic
areas for more than three weeks and will have rural exposure in areas ofrice and pig
farming during the summer months [66-68]. Ifthey will not have such exposure, but
are planning prolonged residence in endemic countries, they should also be vacci-
nated. Until the vaccine is licensed in the United States, travelers should obtain
vaccine in the country of destination. All travelers should exercise prevention
measures against the Culexmosquito, the vector for transmission.
7. Rabies: Although the risk of rabies during travel is very low, all travelers
should be informed about itbecause animal rabies remainsendemic inmany areasof
Latin America, the Far East, and Africa. Those countries which report no cases of
rabies are listed in Health Information for International Travel [2]. Dog rabies
continues to be the major reservoir for transmission to humans, with eight of ten
cases ofrabies in travelers from 1975 to 1984 associated with dog bites [70]. Some of
the dogs had been vaccinated against rabies in the foreign country, raising important
questions about the type and method ofdelivery ofvaccine.
The first step afterbeing bitten by a potentially rabid animal is thorough cleansing
of the wound with soap and water. If the traveler has not received pre-exposure
rabiesprophylaxis, the individual should then seekimmediate post-exposure prophy-
laxis. Pre-exposure prophylaxis does not eliminate the need for prophylaxis after
exposure, but does make the treatment easier by requiring fewer doses of vaccine
and eliminating the need for human rabies immune globulin.
Travelers who should be considered for rabies vaccine are those who will live for
one month or more in an area where rabies is a constant threat [71]. The primary
vaccine available in the United States is the human diploid cell rabies vaccine
(HDCV). An absorbed vaccine adapted to fetal rhesus lung tissue is available to
residents of Michigan from the Michigan Department of Public Health. HDCV can
be administered either intradermally or intramuscularly [71]. Ifvaccination cannot
be completed before initiating malaria chemoprophylaxis, then the intramuscular
route is necessary. The simultaneous administration of chloroquine for malaria
prophylaxis has been shown to decrease the immune response to intradermally
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administered vaccine [72]. Although this phenomenon has not been studied with
mefloquine, it would seem prudent to avoid the intradermal route when mefloquine
is being given. As with other intramuscular vaccines for adults, intramuscular rabies
vaccine should be given in the deltoid muscle in order to assure adequate absorption.
8. Hepatitis Prophylaxis:
Hepatitis A: The highest risk for hepatitis A occurs with travel to rural areas
with poor hygiene, outside the usual tourist routes [73]. Because hepatitis A has
occurred in travelers on standard tourist itineraries, however, most travelers should
be offered protection. Hepatitis A in travelers who have not received prophylaxis
occurs from one to ten times per 1,000 travelers for a two- to three-week stay in the
developing world [74].
Prevention of hepatitis A is achieved with immune globulin (IG), a sterile
preparation of purified antibodies, primarily of IgG type, which contains high titers
against hepatitis A. IG prepared in the United States has not transmitted any viral
infections, including hepatitis B or HIV [75]. The protection conferred by IG is
short-lived, two to three months for the standard dose (0.02 ml/kg) and four to six
months for the higher dose (0.06 ml/kg). For those travelers who remain overseas for
more than six months, regular administration (at four- to six-month intervals) is
necessary. Pre-travel anti-hepatitis A IgG antibody screening may be helpful for
travelers who are frequent visitors to the developing world, or who are likely to have
acquired hepatitis A in the past, and would prefer not to get the intermittent
injections ofIG. Persons who may have acquired hepatitis A previously are those
over the age of 50, those who were born or lived for a prolonged time in the
developing world, and those with a history of hepatitis [76]. Human trials are
currently under way with whole-cell inactivated hepatitis Avaccines, and preliminary
studies have examined live, attenuated, and recombinant vaccines [77,78]. Killed,
whole-cell vaccines seem most promising [79].
Hepatitis B: Hepatitis B is a risk for short- or long-term travelers with exposure
to blood or body fluids, and for long-term travelers (.6 months) to countries with a
high seroprevalence of hepatitis B surface antigen carriage. Those who are at risk
because of exposure are usually physicians, nurses, other health care workers, and
laboratory technicians, and those who are likely to have sexual exposure [73].
Regions with a high prevalence (5 percent to 20 percent) of hepatitis B carriage
include China, southeast Asia, sub-Sahara Africa, the Amazon basin, and parts of
the Middle East.
Vaccines which contain recombinant hepatitis B surface antigen have replaced the
original plasma-derived vaccine in the United States. Hepatitis B vaccines should be
administered intramuscularly in the deltoid in order to assure an optimal response.
One vaccine can be given in a four-dose schedule, with the first three doses given
over two months (Table 1). This timing can allow a more rapid achievement of
immunity prior to travel for those who might require it. To date, vaccine boosting has
not been recommended for the non-compromised host [16,73]. Vaccination against
hepatitis B will protect the traveler against delta hepatitis, since this agent requires
active hepatitis B replication [80].
Enterically Transmitted Hepatitis: A new form of enterically transmitted non-A,
non-B hepatitis has been recognized in Mexico, the Indian subcontinent, and Africa
over the past decade [81]. Several outbreaks [82] have been linked to a fecally
contaminated water source, often after heavy rains [83]. Pregnant women have had a
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TABLE 2
Immunization of the Pregnant Traveler
Vaccine Safety
Bacterial
Tetanus-Diphtheria Yesa
Pneumococcal Yesb
Meningococcal Yesb
Typhoid
Killed No
Live, Attenuated Unknownc
Cholera No
Viral
Poliomyelitis
Inactivated Yes
Live, Attenuated Yes
Yellow Fever Yesd
Measles, Mumps, Rubella No
Influenza Yesa
Rabies Yes
Japanese B Encephalitis Unknownc
Hepatitis B Yes
Immune Globulin Yes
aShould ideally wait until afterthe first trimester
bProbably safe, but has not been studied conclusively
cSafety isunknown, andvaccination should be avoided
until further study.
dShould generally be avoided, but may be given with
high-risk exposure
particularly high mortality rate. Immune globulin preparations manufactured in the
United States are not expected toprevent thisform ofhepatitis [83], and properfood
and liquid sanitation will be the most important mode ofprevention.
IMMUNIZATION OF SPECIAL GROUPS
ThePregnant Traveler
During the pre-travel evaluation of the pregnant traveler, one needs to consider
the likelihood of acquiring a vaccine-preventable disease during the trip, the
consequences of this disease to the mother and her unborn child, and the potential
risks and benefits ofvaccination to both mother and child. There are several sources
which help to assess these factors [2-4,7,8]. While many vaccines may be safely
tolerated duringpregnancy, it isbest to avoidvaccination altogether, ifpossible, or at
least to delay it until after the first trimester. Table 2 lists recommendations for
vaccine administration to pregnant travelers.
1. Bacterial Vaccines: Iftetanus-diphtheria boosting is needed, it can be given
safely, although one should ideally wait until after the first trimester has been
completed. The polysaccharide vaccines, pneumococcal and meningococcal vac-
cines, may be given to high-risk women, although their safety during pregnancy has
not been conclusively studied. The whole-cell, killed bacteria vaccines, typhoid and
cholera, can cause systemic febrile reactions and may put the fetus at risk. They
should, therefore, be avoided. If cholera vaccination is required, a letter ofmedical
contraindication to the vaccine should be sufficient. There is no information on theDAVID R. HILL
use of the new attenuated, live, oral typhoid vaccine. Unless there is a strong
indication, vaccination with this type should probably be avoided. For prevention of
cholera and typhoid fever, emphasis should be placed on food and liquid sanitation.
2. Viral Vaccines: In general, live viral vaccines should be avoided during
pregnancy. If, however, there is substantial risk for poliomyelitis during travel, either
OPV or eIPV can be given. Travel to areas where yellow fever epidemics are
occurring should be postponed until after pregnancy. If travel cannot be avoided,
however, the pregnant traveler may be vaccinated. For those going to an area where
the actual risk of disease from yellow fever is minimal, but vaccine is required, a
letter of medical contraindication may be given. Vaccination against measles,
rubella, or mumps should be deferred until after pregnancy.
Women who are at high risk for complications from influenza may be immunized.
Pre-exposure rabies vaccine is also considered safe for women at risk. Because ofthe
potentially severe consequences of hepatitis B in children born to women with
hepatitis B infection, vaccination may be considered. There is no information on the
safety of Japanese B encephalitis vaccine in pregnant women, and it should be
avoided until further information is gained. Administration of immune globulin for
the passive prophylaxis of hepatitis A is safe.
The HIV-Infected Traveler
The high prevalence of HIV infection emphasizes the need to assess a traveler's
risk factors for HIV. If a traveler is found to be infected with HIV, there are several
important issues to consider when counseling such an HIV-infected traveler. First,
many countries have instituted HIV testing for long-term travelers, which could
result in an individual being barred from entry or residence within a country [84,85].
Second, many diseases such as salmonellosis, cryptosporidium, tuberculosis, and
leishmaniasis are more prevalent in the developing world and may have more severe
or prolonged clinical courses in HIV-infected or AIDS travelers [12,86-89]. Finally,
access to sophisticated medical care may be limited, increasing the potential morbid-
ity from an HIV-associated illness such as Pneumocystis carinii pneumonia.
The two issues of efficacy and safety also apply to immunizing HIV-infected
travelers [9-12]. Many vaccines are less immunogenic in HIV-positive individuals,
and response rates decline as HIV infection advances [90]. Moreover, there are
theoretical risks of progressive, disseminated infections with attenuated live vac-
cines, as has occurred with BCG and vaccinia virus [91,92]. In contrast, the morbidity
from measles outweighs the theoretical risk ofvaccine toxicity [93,94]. Each of these
issues needs to be considered and discussed with the HIV-infected traveler prior to
vaccine administration. Table 3 provides guidelines for the immunization of asymp-
tomatic HIV-infected travelers and those with symptomatic infection and AIDS. It
may be reasonable to determine the CD4 lymphocyte count prior to vaccine
administration, both to predict the potential response to vaccination and to assess
the potential risk of the vaccine [12].
1. Bacterial Vaccines: The inactivated bacterial vaccines can be given safely.
Tetanus-diphtheria should be given by the routine schedule. Because HIV-infected
persons are at increased risk from infections with encapsulated bacteria, they should
be protected with both pneumococcal and Hemophilus influenzae vaccines. Meningo-
coccal vaccine should be given to those who travel to areas of risk. Although there is
no data on the safety of the live, attenuated vaccine against S. typhi, it would be
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TABLE 3
Immunization ofthe HIV-Infected Traveler
HIV Infection
Vaccine Asymptomatic Symptomatic
Bacterial
Tetanus-Diphtheria Yes Yes
Pneumococcal Yes Yes
Meningococcal Yes Yes
Typhoid
Killed Yes Yes
Live, Attenuated Unknownc Unknownc
Cholera Yes Yes
BCG No No
Viral
Poliomyelitis
Inactivated Yes Yes
Live, Attenuated No No
Yellow Fever Yesa No
Measles, Mumps, Rubella Yes Yesb
Influenza Yes Yes
Rabies Yes Yes
Japanese B Encephalitis Unknownc Unknownc
Hepatitis B Yes Yes
Immune Globulin Yes Yes
aProbably safe but has not been conclusively studied
bShould be considered; safety has not been conclusively demon-
strated.
cSafety is unknown, and vaccination should be avoided until further
study.
Source: Adapted from [7]
prudent to avoid this type and togive the killed, whole-cell preparation. The minimal
risk for cholera and poor vaccine efficacy do not justify routine vaccination. Some
AIDS patients maybe at higher risk for enteric organisms because oflowered gastric
acidity, however, and for these travelers at risk for cholera, vaccination may be
considered [95]. BCG vaccination is unnecessary, may be dangerous, and should be
avoided.
2. Viral Vaccines: Inactivated viral vaccines should be used for protection
against viral illness. Influenza immunization should be given annually to HIV-
infected patients. Protection against polio should be achieved with eIPV rather than
with OPV because of the risk of vaccine-associated paralysis. Because of the high
incidence of hepatitis B infection in the HIV-infected population, pre-vaccination
screening for hepatitis B antigen and antibody should be done. Ifrabies prevention is
needed, the intramuscular route ofadministration should be used in order to assure
the maximum immune response. There is no information on safety or efficacy of
Japanese B encephalitis vaccine in immunocompromised hosts. Immune globulin
maybe administered safely.
Althoughyellow fevervaccine hasbeen demonstrated tobeverysafe aftermillions
ofdoses, rare cases ofvaccine-associated encephalitis have occurred. Because ofthe
theoretical risk ofencephalitis in immunosuppressed patients, vaccination should be312 DAVID R. HILL
avoided in symptomatic HIV-infected patients. These travelers should also avoid
areas ofthe world where outbreaks ofyellow fever are occurring [36,38]. Ifexposure
is unavoidable for the symptomatically infected traveler, a letter ofmedical contrain-
dication should be provided, and the individual should be instructed on rigorous
avoidance of mosquitoes. For the asymptomatic HIV-infected traveler, vaccination
can be offered after the risks are explained. Because the immune response may be
diminished, it maybe wise to check post-vaccination titers.
The consequences ofmeasles in unprotected HIV-infected persons may be severe
[94]. Because ofthe severityofthe illness and the safetyofvaccination, HIV-infected
travelers at risk for measles should be immunized. This precaution should be done
routinelyforasymptomaticpatientsandconsideredforat-riskpatientswithsymptom-
atic HIV infection.
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